Potential of capsaicin as a combinatorial agent to overcome chemoresistance and to improve outcomes of cancer therapy
Files
(Published version)
Date
2025
Authors
Sailo, B.L.
Garhwal, A.
Mishra, A.
Hegde, M.
Vishwa, R.
Girisa, S.
Abbas, M.
Alqahtani, M.S.
Abdulhammed, A.
Sethi, G.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Biochemical Pharmacology, 2025; 236(116828)
Statement of Responsibility
Conference Name
Abstract
Capsaicin (CAPS), a bioactive alkaloid derived from chili peppers, has garnered significant interest for its potential role as a combinatorial and chemosensitizing agent in cancer therapy. Numerous preclinical studies have demonstrated that CAPS enhanced the efficacy of various anticancer agents by promoting apoptosis, modulating autophagy and inhibiting angiogenesis, tumor growth, and metastasis. Additionally, CAPS modulated critical regulators of chemoresistance, such as P-glycoprotein (P-gp), extracellular signal-regulated kinase (ERK), nuclear factor-kappa B (NF-κB) pathway, and signal transducer and activator of transcription 3 (STAT3) pathway, thereby contributing to the reversal of multidrug resistance (MDR). Moreover, when administered in combination with chemotherapeutic agents, CAPS has been shown to improve treatment efficacy at lower drug concentrations. Given its multitargeted mechanism of action, CAPS represents a promising adjunct to conventional cancer therapies. However, due to its lipophilic nature, the development of optimized formulation strategies is essential to enhance its bioavailability and ensure consistent therapeutic outcomes. In conclusion, CAPS holds significant potential as a combinatorial and chemosensitizing agent, helping to overcome chemoresistance and enhance treatment outcomes across various malignancies. These promising findings warrant further preclinical and clinical investigations.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2025 The Authors. (http://creativecommons.org/licenses/by/4.0/)
Access Condition Notes: This is an open access article under the CC BY license